Here are relevant reports on : traumatic-brain-injury-rehabilitation-therapy-market
-
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035
The global radioligand therapy market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.2% from 2025 to 2035, culminating in a forecasted valuation of US$10.91 billion by the end of the period. The growth of this market is primarily attributed to factors such as increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, and the rising adoption of PSMA and SSTR PET imaging for patient selection.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Ultrasonic Tissue Ablation System Market by Type (HIFU Ablators, MRGFUS Ablators, Ultrasonic Surgical Ablation, Shock Wave Therapy Systems), Application (Cardiac Diseases, Cancer, Pain Management) & End User (Hospitals, Clinics) - Global Forecast to 2023
The global ultrasonic tissue ablation system market is expected to reach USD 1,449.2 million by 2023 from USD 840.9 million in 2018, growing at a CAGR of 11.5%. Increasing prevalence of chronic diseases; rising adoption of minimally invasive surgeries; ongoing technological advancements in the field of ablation devices, growing awareness about benefits of ablation procedures over conventional therapeutic and surgical procedures, and rising number of hospitals and surgical centers are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new devices, thus propelling the market growth.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region - Global Forecast to 2028
The global continuous renal replacement therapy market, valued at US$1.3 billion in 2022, stood at US$1.4 billion in 2023 and is projected to advance at a resilient CAGR of 8.1% from 2023 to 2028, culminating in a forecasted valuation of US$2.1 billion by the end of the period. Various factors such as rise in worldwide prevalence of AKI, Growing number of ICU patients with AKI and rising incidences of sepsis, and growing clinical advantage of CRRT over intermittent blood purification are factors likely to accelerate the growth of the market.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Healthcare Market Outlook – [By Health Indicators (Life Expectancy, Mortality), Disease Burden (Epidemiology, Average Cost Of Therapy), Health System (Infrastructure, Expenditure), Regulatory Landscape] - Analysis & Forecast To 2020
The APAC region showcases diverse healthcare challenges across various countries. These range from improving healthcare access in developing countries of Vietnam to tackling rising diabetes, cancer, and cardiovascular diseases in well developed nations of Japan and Pacific countries. In addition, regions of China and India that lie in between developing and well developed countries are facing increase in diseases burden, problems of poverty, limited access to high quality treatment, and slow increase in disposable income. The APAC Healthcare Market Outlook examines the health indicators and healthcare system across India, China, Japan, Singapore, Indonesia, Thailand, Malaysia, Vietnam, Australia, and New Zealand. The APAC Healthcare Market Outlook is segmented into five broad categories: health status, healthcare system assessment, healthcare regulatory landscape, medical devices infrastructure assessment, hospital chain assessment in top 10 hospitals.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021
The global plasma therapy market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021. Factors driving the growth of the plasma therapy market include rising incidences of trauma and increasing healthcare expenditure worldwide.
- Published: July 2016
- Price: $ 4950
- TOC Available:
-
Elastomeric Pumps Market by Product (Continuous Rate, Variable Rate), Treatment (Chemotherapy, Antibiotic, Iron Chelation Therapy), Administration Route (Intravenous, Subcutaneous), End User (Hospital, Ambulatory Surgery Center) - Global Forecast to 2022
The global elastomeric pumps market is expected to reach USD 592.0 Million by 2022 from USD 432.1 Million in 2017, growing at a CAGR of 6.5% from 2017 to 2022. Increasing number of surgeries, wide usage in treatment, rising incidence of chronic diseases, and increasing adoption for disposable infusion pumps, are some of the major driving factors driving the growth of the global elastomeric pumps market. However, the high cost of treatment and challenges in reimbursement are hindering the growth of this market to a certain extent.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Biophotonics Market by Application(See-through Imaging, Inside Imaging, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors), Technology(In-vivo, In-vitro), End-use(Diagnostics, Therapeutic, Tests), & Geography - Global Forecast to 2020
The overall market for biophotonics in 2014 was valued at USD 26.26 Billion, which is estimated to reach USD 50.18 Billion by 2020, at a CAGR of 11.5% during the forecast period. This market growth can be attributed to emergence of nanotechnology, significant technological advancements over the last few years and their adoption in the medical sector, increase in the demand for home-based POC devices, aging population, and growing lifestyle diseases.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
Autoinjectors Market by Type (Devices, Finished Formulation), Usage (Disposable, Reusable), Actuation Mechanism (Mechanical, Electronic), Therapy (Rheumatoid Arthritis, Obesity, Diabetes), ROA (SC, IM), Volume (< 3ml, > 3ml) - Global Forecast to 2031
The global autoinjectors market, valued at USD 107.60 billion in 2025, stood at USD 127.30 billion in 2026 and is projected to advance at a resilient CAGR of 18.7% from 2026 to 2031, culminating in a forecasted valuation of USD 300.46 billion by the end of the period. Some of the leading companies in the device-only autoinjectors market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). Key players in the finished formulation autoinjectors market include Novo Nordisk (Denmark), AbbVie Inc. (US), and Eli Lilly and Company (US).
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Robotic Radiotherapy Market Size by Product (System, Software, 3D Camera), Technology (LINAC, Stereotactic, Particle Therapy), Application (Lung, Breast, Colorectal), End-User (Hospitals, Radiotherapy Centres), & Region - Global Forecast to 2028
The global robotic radiotherapy market, valued at US$0.8 billion in 2021, stood at US$1.1 billion in 2023 and is projected to advance at a resilient CAGR of 11.9% from 2023 to 2028, culminating in a forecasted valuation of US$1.9 billion by the end of the period. The market's expansion is driven by several factors, including the global rise in cancer cases, advancements in automation technologies enhancing the precision of radiotherapy, a growing preference for non-invasive cancer treatments, and the rapid proliferation of cancer treatment facilities.
- Published: April 2024
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
